ID   K562-r
DR   ATCC; CRL-3344
DR   Wikidata; Q94335706
RX   PubMed=10910924;
CC   Doubling time: ~24-30 hours (ATCC).
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: BCR-ABL1 gene fusion (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Gln136fs*13 (c.406_407insC) (from parent cell line).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 02-07-20; Version: 4
RX   PubMed=10910924; DOI=10.1182/blood.V96.3.1070;
RA   Mahon F.-X., Deininger M.W.N., Schultheis B., Chabrol J., Reiffers J.,
RA   Goldman J.M., Melo J.V.;
RT   "Selection and characterization of BCR-ABL positive cell lines with
RT   differential sensitivity to the tyrosine kinase inhibitor STI571:
RT   diverse mechanisms of resistance.";
RL   Blood 96:1070-1079(2000).